Abstract 1259: Loss of TFF1 Promotes Growth and Chemotherapeutic Resistance in Gastric Cancer
Zheng Chen,Zheng Li,Mohammed Soutto,Weizhi Wang,Shoumin Zhu,Alejandro Corvalan,Zekuan Xu,Wael El-Rifai
DOI: https://doi.org/10.1158/1538-7445.am2018-1259
IF: 11.2
2018-01-01
Cancer Research
Abstract:Abstract Background: Downregulation or loss of TFF1 expression occurs in more than half of human gastric adenocarcinomas through gene deletions, mutation, and a loss of heterozygosity or hypermethylation. Our previous studies have shown that Tff1 knockout (KO) in mice induces gastric lesions from low- grade dysplasia (LGD), high- grade dysplasia (HGD) to adenocarcinoma. BRD2, a family member of BET proteins, promotes aberrant gene expression in a variety of malignant tumors. In this study, with the analysis of Tff1 KO mice and human gastric cancer tissue samples, we discovered that loss of Tff1 promotes gastric cancer proliferation and drug resistance through upregulating BRD2 expression level. Methods and Results: Integration Next Generation Sequencing data analysis in both Tff1 KO mice and human gastric cancer tissue samples demonstrated that miR-143-3p was significantly down-regulated in both mice and human gastric cancer samples (P<0.05). Our findings were further validated by RT-PCR in Tff1 KO mouse gastric legions (LGD and adenocarcinoma) and 3 different cohorts of human gastric cancer tissue samples from USA, Chile, and China. Using different gastric cancer cell models we further confirmed the decrease of miR-143-3p regulated by loss of TFF1. Next, we wanted to find out the downstream effector of miR-143-3p down-regulation. Western blot data showed that BRD2 protein level was regulated by miR-143-3p in 4 gastric cancer cell lines. BRD2 3'UTR luciferase reporter assay further confirmed that miR-143-3p decreased BRD2 protein expression through directly binding to its 3'UTR sites. These data suggested that, for the first time, BRD2 is a direct downstream target of miR-143-3p. At the meantime, the reconstitution of TFF1 in gastric cancer cells up-regulated miR-143-3p expression level, which in turn, decreased the protein expression levels of BRD2, MYC and BCL-2. Using western blot, we showed the synergistic effect of BRD2 inhibitor and CDDP chemotherapy in human gastric cancer cells. Data from 320 human gastric cancer patients demonstrated that high BRD2 expression level in gastric cancer tissues significantly decreased the overall patient survival rate (P<0.0001). Conclusion: This study unveils, for the first time, loss of TFF1 promotes BRD2 activation in gastric cancer through decreasing miR-143-3p. This axis presents novel therapeutic opportunities by using approaches that reconstitute miR-143-3p or utilizing the recently developed clinical trials in human gastric cancer. Citation Format: Zheng Chen, Zheng Li, Mohammed Soutto, Weizhi Wang, Shoumin Zhu, Alejandro Corvalan, Zekuan Xu, Wael El-Rifai. Loss of TFF1 promotes growth and chemotherapeutic resistance in gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1259.